Single-arm P2 study | Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy.

Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)

News Release: Some breast cancer patients with high responses to chemotherapy may not need surgery: Biopsy protocol identifies patients at low risk of recurrence – University of Texas M. D. Anderson Cancer Center

Commentary: Elimination of Surgery Explored for Selected Breast Cancer Patients – HealthDay

Commentary on Twitter

Online first: #Eliminating breast #surgery for invasive #breastcancer in exceptional #responders to #neoadjuvant systemic #therapy: a multicentre, single-arm, phase 2 trial https://t.co/lxZa62zFZT pic.twitter.com/TS1dKqFhF1

— The Lancet Oncology (@TheLancetOncol) October 26, 2022